Anergis is a clinical-stage biopharmaceutical company based in Epalinges, Switzerland, focused on developing innovative immunotherapies for allergic diseases. Its lead product, AllerT, targets patients allergic to birch pollen. The company plans to run a large Phase II multicenter trial of AllerT. It will also accelerate preclinical development of its broader product portfolio in new research laboratories. The CHF18m Series A financing is expected to cover the company’s financial requirements for the next two years. Anergis is led by CEO Vincent Charlon, PhD, and its board will be chaired by André J. Mueller. Representatives of the lead investors have joined the board to support development and oversight.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2011